Back

Kinetics of antibody responses dictate COVID-19 outcome

2020-12-22 allergy and immunology Title + abstract only
View on medRxiv
Show abstract

Recent studies have provided insights into innate and adaptive immune dynamics in coronavirus disease 2019 (COVID-19). Yet, the exact feature of antibody responses that governs COVID-19 disease outcomes remain unclear. Here, we analysed humoral immune responses in 209 asymptomatic, mild, moderate and severe COVID-19 patients over time to probe the nature of antibody responses in disease severity and mortality. We observed a correlation between anti-Spike (S) IgG levels, length of hospitalization...

Predicted journal destinations

1
Nature Communications
483 training papers
Top 4% 16.9%
2
Frontiers in Immunology
140 training papers
Top 0.7% 11.3%
3
Cell Reports Medicine
49 training papers
#1 7.4%
4
Clinical Infectious Diseases
219 training papers
Top 4% 6.1%
5
The Journal of Infectious Diseases
137 training papers
Top 1% 5.7%
6
eLife
262 training papers
Top 8% 4.8%
7
PLOS ONE
1737 training papers
Top 83% 4.8%
8
Cell
28 training papers
Top 0.2% 3.7%
9
Journal of Clinical Investigation
50 training papers
Top 0.9% 3.7%
10
The Journal of Immunology
19 training papers
Top 0.4% 3.7%
11
Science Translational Medicine
40 training papers
Top 0.4% 2.7%
12
Scientific Reports
701 training papers
Top 74% 2.7%
13
Nature Medicine
88 training papers
Top 3% 1.8%
14
mSphere
27 training papers
Top 0.2% 1.8%
15
Vaccine
140 training papers
Top 4% 1.8%
16
Journal of Medical Virology
95 training papers
Top 8% 1.5%
17
npj Vaccines
18 training papers
Top 0.2% 1.5%
18
Science Immunology
15 training papers
Top 0.4% 1.5%
19
JCI Insight
63 training papers
Top 5% 1.3%
20
Vaccines
131 training papers
Top 8% 1.3%
21
Nature
58 training papers
Top 8% 0.9%
22
Proceedings of the National Academy of Sciences
100 training papers
Top 17% 0.9%
23
Viruses
79 training papers
Top 8% 0.9%
24
eBioMedicine
82 training papers
Top 10% 0.9%
25
Cell Reports
25 training papers
Top 3% 0.7%
26
iScience
74 training papers
Top 14% 0.7%